These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 21689708)
1. Vaccine Technology III: an ECI Conference held in Puerto Vallarta, Mexico from June 6-11, 2010. Buckland BC; Aunins JG; Jansen K; Alves PM; Weiner D Vaccine; 2011 Sep; 29(41):7115-6. PubMed ID: 21689708 [No Abstract] [Full Text] [Related]
2. Vaccine Technology III. Advances in vaccine technology. Proceedings of the ECI Conference. June 6-11. 2011. Puerto Vallarta, Mexico. Vaccine; 2011 Sep; 29(41):7115-217. PubMed ID: 22256364 [No Abstract] [Full Text] [Related]
3. Methods in vaccine effectiveness and safety studies: a critical need for vaccine confidence. Jacobsen SJ; Poland GA Vaccine; 2011 Dec; 29(52):9573-4. PubMed ID: 22051135 [No Abstract] [Full Text] [Related]
4. Vaccine Technology IV: an ECI Conference held in Albufeira, Portugal from May 20 to 24, 2012. Weiner DB; Buckland B Vaccine; 2014 May; 32(24):2763-6. PubMed ID: 24583001 [No Abstract] [Full Text] [Related]
5. Letter from the editor. Ellis RW; Riedmann EM Hum Vaccin Immunother; 2012 Mar; 8(3):281. PubMed ID: 22418878 [No Abstract] [Full Text] [Related]
11. Domestic influenza vaccine production in Mexico: a state-owned and a multinational company working together for public health. Ponce-de-Leon S; Velazquez-Fernandez R; Bugarin-González J; García-Bañuelos P; Lopez-Sotelo A; Jimenez-Corona ME; Padilla-Catalan F; Cervantes-Rosales R Vaccine; 2011 Jul; 29 Suppl 1():A26-8. PubMed ID: 21684424 [TBL] [Abstract][Full Text] [Related]
12. Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Bae K; Choi J; Jang Y; Ahn S; Hur B Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962 [TBL] [Abstract][Full Text] [Related]
13. Vaccine research and development. Ellis RW; Riedmann EM Hum Vaccin; 2010 Nov; 6(11):865. PubMed ID: 21415601 [No Abstract] [Full Text] [Related]
14. New technologies: only a snapshot, but look how far we have come! Gavins FN Curr Opin Pharmacol; 2012 Oct; 12(5):567-8. PubMed ID: 22944252 [No Abstract] [Full Text] [Related]
15. Industry outlines its perspective on new third-world vaccine development. Birmingham K Nat Med; 2000 Jul; 6(7):723-4. PubMed ID: 10888899 [No Abstract] [Full Text] [Related]
16. The Vaccine Formulation Laboratory: a platform for access to adjuvants. Collin N; Dubois PM Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427 [TBL] [Abstract][Full Text] [Related]
18. Deal watch: Trends in platform technology deal-making. Walker J; Jacob J Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395 [No Abstract] [Full Text] [Related]
19. Terrapinn's world influenza congress Europe 2009. Part 2. Veryard C IDrugs; 2010 Feb; 13(2):78-9. PubMed ID: 20127556 [TBL] [Abstract][Full Text] [Related]
20. Next generation personalized animals as an enabling technology in personalized vaccinology. Poland GA; Mirochnitchenko O Vaccine; 2013 Jan; 31(5):725-7. PubMed ID: 23337595 [No Abstract] [Full Text] [Related] [Next] [New Search]